WO2005053505A8 - Uso del gen ncsag4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia - Google Patents

Uso del gen ncsag4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia

Info

Publication number
WO2005053505A8
WO2005053505A8 PCT/ES2004/000529 ES2004000529W WO2005053505A8 WO 2005053505 A8 WO2005053505 A8 WO 2005053505A8 ES 2004000529 W ES2004000529 W ES 2004000529W WO 2005053505 A8 WO2005053505 A8 WO 2005053505A8
Authority
WO
WIPO (PCT)
Prior art keywords
neosporosis
pathogenesis
diagnosis
prevention
analysis
Prior art date
Application number
PCT/ES2004/000529
Other languages
English (en)
French (fr)
Other versions
WO2005053505A3 (es
WO2005053505A2 (es
Inventor
Mora Luis Miguel Ortega
Garcia Aurora Fernandez
Original Assignee
Univ Madrid Complutense
Mora Luis Miguel Ortega
Garcia Aurora Fernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Complutense, Mora Luis Miguel Ortega, Garcia Aurora Fernandez filed Critical Univ Madrid Complutense
Priority to US10/581,810 priority Critical patent/US7579438B2/en
Priority to MXPA06006381A priority patent/MXPA06006381A/es
Priority to CA002548582A priority patent/CA2548582A1/en
Priority to NZ547735A priority patent/NZ547735A/en
Priority to AU2004294741A priority patent/AU2004294741B2/en
Priority to JP2006541962A priority patent/JP2007516705A/ja
Priority to BRPI0417237-0A priority patent/BRPI0417237A/pt
Priority to EP04805072A priority patent/EP1710309B1/en
Priority to ES04805072T priority patent/ES2390775T3/es
Publication of WO2005053505A2 publication Critical patent/WO2005053505A2/es
Publication of WO2005053505A3 publication Critical patent/WO2005053505A3/es
Publication of WO2005053505A8 publication Critical patent/WO2005053505A8/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al gen NsSAG4, su RNA mensajero, los oligocluneótidos diseñados en función de su secuencia nucleotídica, o cualquiera de sus fragmentos, así como la proteina NcSAG4 que codifia, o cualquiera de sus formas recombinantes, los vectores de expresión, así como las células hospedodoras que los contengan, para el diagnóstico y la vacunación para la prevención de la neosporosis, así como su uso como marcador específico de la fase de bradizoíto de N. caninum, para el análisis de la patogenia o de la eficacia de las vacunas frente al establecimiento de la infección crónica en el hospedador intermediario.
PCT/ES2004/000529 2003-12-04 2004-11-26 Uso del gen ncsag4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia WO2005053505A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/581,810 US7579438B2 (en) 2003-12-04 2004-11-26 Use of the gene NcSAG4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
MXPA06006381A MXPA06006381A (es) 2003-12-04 2004-11-26 Uso del gen ncsag4 para el diagnostico y prevencion de la neosporosis, y como marcador para el analisis de la patogenia.
CA002548582A CA2548582A1 (en) 2003-12-04 2004-11-26 Use of gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
NZ547735A NZ547735A (en) 2003-12-04 2004-11-26 Use of gene NCSAG4 from Neospora caninum for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
AU2004294741A AU2004294741B2 (en) 2003-12-04 2004-11-26 Use of gene NcSAG4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
JP2006541962A JP2007516705A (ja) 2003-12-04 2004-11-26 ＮｃＳＡＧ４のネオスポラ病の診断および予防のための使用ならびに発症機序の解析用マーカーとしての使用
BRPI0417237-0A BRPI0417237A (pt) 2003-12-04 2004-11-26 uso de gene ncsag4 diagnóstico e prevenção de neosporose e como marcador para análise de patogênese
EP04805072A EP1710309B1 (en) 2003-12-04 2004-11-26 Use of gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
ES04805072T ES2390775T3 (es) 2003-12-04 2004-11-26 Uso del gen NcSAG4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302869A ES2263317B2 (es) 2003-12-04 2003-12-04 Uso del gen ncsag4 para el diagnostico y prevencion de la neosporosis, y como marcador para el analisis de la patogenia.
ESP200302869 2003-12-04

Publications (3)

Publication Number Publication Date
WO2005053505A2 WO2005053505A2 (es) 2005-06-16
WO2005053505A3 WO2005053505A3 (es) 2005-07-14
WO2005053505A8 true WO2005053505A8 (es) 2007-03-29

Family

ID=34639545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2004/000529 WO2005053505A2 (es) 2003-12-04 2004-11-26 Uso del gen ncsag4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia

Country Status (12)

Country Link
US (1) US7579438B2 (es)
EP (1) EP1710309B1 (es)
JP (1) JP2007516705A (es)
CN (1) CN1902314A (es)
AU (1) AU2004294741B2 (es)
BR (1) BRPI0417237A (es)
CA (1) CA2548582A1 (es)
ES (2) ES2263317B2 (es)
MX (1) MXPA06006381A (es)
NZ (1) NZ547735A (es)
RU (1) RU2006123551A (es)
WO (1) WO2005053505A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326770B1 (es) * 2007-07-13 2010-07-26 Universidad Complutense De Madrid Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora.
CN101831495B (zh) * 2010-04-30 2013-06-19 新疆出入境检验检疫局检验检疫技术中心 一种牛新孢子虫病的检测方法及应用
CN102888412B (zh) * 2012-09-21 2018-02-09 吉林大学 一种新孢子虫特异pcr检测试剂盒及制备方法
CN111197100B (zh) * 2020-01-14 2021-09-14 中国农业大学 犬新孢子虫特异pcr检测试剂盒及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2306642A1 (en) * 1997-10-20 1999-04-29 Bayer Corporation Neospora vaccines
EP0924295A3 (en) * 1997-12-04 2001-05-16 Pfizer Products Inc. DNA encoding neospora dihydrofolate reductase-thymidylate synthase
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby

Also Published As

Publication number Publication date
MXPA06006381A (es) 2006-08-25
CN1902314A (zh) 2007-01-24
NZ547735A (en) 2009-09-25
JP2007516705A (ja) 2007-06-28
EP1710309B1 (en) 2012-07-04
US20070275018A1 (en) 2007-11-29
US7579438B2 (en) 2009-08-25
AU2004294741B2 (en) 2011-10-06
BRPI0417237A (pt) 2007-03-06
ES2390775T3 (es) 2012-11-16
WO2005053505A3 (es) 2005-07-14
ES2263317A1 (es) 2006-12-01
EP1710309A2 (en) 2006-10-11
CA2548582A1 (en) 2005-06-16
WO2005053505A2 (es) 2005-06-16
RU2006123551A (ru) 2008-01-10
AU2004294741A1 (en) 2005-06-16
ES2263317B2 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
WO2005070958A3 (en) Lawsonia intracellularis subunit vaccines
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2000066739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
IL169367A0 (en) Defensin proteins
EP2289544A3 (en) Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2003054012A3 (en) Leptin proteins
WO2005053505A3 (es) Uso del gen ncsag4 para el diagnóstico y prevención de la neosporosis, y como marcador para el análisis de la patogenia
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
UA93658C2 (en) Cell surface glycoprotein
SI1565573T1 (sl) Sonde nukleinske kisline in primerji širokega območja iz regij v topoizomeraznih genih ter postopki, pri katerih jih uporabljamo
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2006084694A3 (en) Use of the mcm8 gene for the preparation of a pharmaceutical composition
ZA200607741B (en) Beak and feather disease virus sequences, compositions and vaccines and the use thereof in therapy, diagnosis and assays
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
HUP0200832A2 (hu) Babesia canis oltóanyag
WO2003023027A3 (de) Tt-virus-sequenzen in menschlichen tumorgeweben, mittel zu deren nachweis sowie tumortherapie
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2003100061A3 (en) Three finger toxin fold proteins
WO2005001096A8 (fr) Vaccins contre le sras
WO2003076668A3 (de) Verfahren zum identifizieren von spezifischen rna-inhibitoren
WO2006051333A3 (en) Leucine-rich repeat (lrr) motif containing proteins
WO2004035626A3 (en) Alpha macroglobulin protein family members
WO2007049062A3 (en) Vwfa-domain containing proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2548582

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006381

Country of ref document: MX

Ref document number: 2006541962

Country of ref document: JP

Ref document number: 3228/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 547735

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004294741

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004805072

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006123551

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004294741

Country of ref document: AU

Date of ref document: 20041126

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200480039992.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004294741

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2004805072

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0417237

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10581810

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10581810

Country of ref document: US